Sanofi Pasteur completes acquisition of Acambis
This article was originally published in Scrip
Executive Summary
Sanofi Pasteurhas completed its acquisition of the UK-based vaccine developer Acambis for £285 million. The amount has increased from the £276 million that was proposed in Sanofi Pasteur's offer in July, primarily due to stock options. The acquisition will strengthen Sanofi Pasteur's R&D unit with projects such as the development of a Clostridium difficile vaccine, an influenza vaccine based on M2 protein and a pre-clinical programme to develop a vaccine against herpes.
You may also be interested in...
Myotec and Hybrid merge to form PsiOxus
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
Trophos's MitoCare programme receives €6 million EU funding
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Novartis and Alcon reach compromise to settle merger saga
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.